Sort   by:  
 Page size 
UnknownA randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
Not available
S-EPMC7224085 | biostudies-literature
UnknownUsability of rectal swabs for microbiome sampling in a cohort study of hematological and oncological patients.
Not available
S-EPMC6464231 | biostudies-literature
UnknownA phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
Not available
S-EPMC4486224 | biostudies-literature
UnknownImprovements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors.
Not available
S-EPMC11285951 | biostudies-literature
UnknownTargeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma.
Not available
S-EPMC10325704 | biostudies-literature
UnknownLong-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
Not available
S-EPMC5303616 | biostudies-literature
UnknownInflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer.
Not available
S-EPMC12325939 | biostudies-literature
UnknownSafety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Not available
S-EPMC6068045 | biostudies-literature
UnknownCisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Not available
S-EPMC3933250 | biostudies-literature
UnknownRandomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).
Not available
S-EPMC12875868 | biostudies-literature
Sort   by:  
 Page size